SCHEMBL6783334

SCHEMBL6783334

COc1cc2ncnc(Nc3ccc(C)c(N)c3)c2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.74
RET P07949 5/20 0.74
KIF5B P33176 2/20 0.74
EGFR P00533 15/20 0.72
CLK1 P49759 1/20 0.72
ABCG2 Q9UNQ0 1/20 0.72
LCK P06239 5/20 0.70
FLT1 P17948 1/20 0.65
GAK O14976 1/20 0.65
RIPK2 O43353 1/20 0.65
STK10 O94804 1/20 0.65
FLT3 P36888 1/20 0.65
JAK3 P52333 1/20 0.65
AAK1 Q2M2I8 1/20 0.65
Q6ZSR9 Q6ZSR9 1/20 0.65
SLK Q9H2G2 1/20 0.65
IRAK4 Q9NWZ3 1/20 0.65
RPS6KA6 Q9UK32 1/20 0.65
ALK Q9UM73 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565204 0.88 KDR (0.79) KDRRETKIF5BEGFRCLK1
SCHEMBL6792594 0.86 EGFR (0.74) KDRRETKIF5BEGFRCLK1
SCHEMBL6787016 0.86 KDR (0.74) KDRRETKIF5BEGFRCLK1
SCHEMBL3533221 0.85 EGFR (0.80) KDRRETKIF5BEGFRCLK1
SCHEMBL5865262 0.85 EGFR (0.81) KDRRETKIF5BEGFRCLK1
SCHEMBL5651286 0.85 KDR (1.00) KDRRETKIF5BEGFRCLK1
Hydrochloric Acid SCHEMBL8871198 0.84 EGFR (0.80) KDRRETKIF5BEGFRCLK1
SCHEMBL5565137 0.84 EGFR (1.00) KDRRETKIF5BEGFRCLK1
SCHEMBL20812874 0.84 EGFR (0.80) KDRRETKIF5BEGFRCLK1
SCHEMBL1483638 0.84 EGFR (0.71) KDRRETKIF5BEGFRCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1158266-C Chemical compounds 2004-07-21 CN disclosed
US-6716847-B2 ANTIALLERGENS, ANTIINFLAMMATORY ASTRAZENECA AB (SE) 2004-04-06 US disclosed
US-6593333-B1 Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various ASTRAZENECA AB (SE) 2003-07-15 US disclosed
EP-1117653-B1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-02-05 EP disclosed
CN-1321151-A Chemical compounds ASTRAZENECA AB (SE) 2001-11-07 CN disclosed
EP-1117653-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2001-07-25 EP disclosed
WO-2000020402-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2000-04-13 WO disclosed